ARTICLE | Company News
Amgen, VGNX in pharmacogenomics deal
January 4, 2001 8:00 AM UTC
Variagenics (VGNX) will use its Variagenic Impact Program (VIP) to develop assays for an undisclosed therapeutic for AMGN. VIP uses bioinformatics software and experiments to measure haplotypes that c...